← Back to Search

CAR T-cell Therapy

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by AgenTus Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through day 28 post cell infusion
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new treatment using special immune cells from healthy donors to help patients whose multiple myeloma has come back or didn't respond to other treatments. The goal is to see if this treatment is safe and effective. The immune cells are meant to strengthen the patient's ability to fight cancer.

Eligible Conditions
  • Relapsed or Refractory Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through day 28 post cell infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through day 28 post cell infusion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number Of Participants With Treatment-related Adverse Events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Allogeneic iNKT CellsExperimental Treatment1 Intervention
3+3 Dose escalation of agenT-797 will be administered by intravenous infusion every 2 weeks (each cycle is 14 days \[2 weeks\]).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
agenT-797
2022
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

AgenTus Therapeutics, Inc.Lead Sponsor
MiNK TherapeuticsLead Sponsor
2 Previous Clinical Trials
54 Total Patients Enrolled
Medical DirectorStudy DirectorMiNK Therapeutics
2,900 Previous Clinical Trials
8,090,421 Total Patients Enrolled
26 Trials studying Multiple Myeloma
4,567 Patients Enrolled for Multiple Myeloma
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top